1. Scrip
  3. >>Strategy

Cloud Pharmaceuticals' Don Van Dyke On Applying Cloud Computing To Drug Discovery

 
• By Joseph Haas

Biotech uses cloud computing and artificial intelligence to accelerate the discovery and design of small-molecule drug candidates across a broad range of therapeutic areas.

Boston – Cloud Pharmaceuticals Inc. Chief Operating Officer Don Van Dyke spoke with Scrip at BioPharm America 2016 about how the company uses cloud computing to accelerate the discovery and design of novel small-molecule drug candidates in therapeutic areas such as cancer, inflammatory disease, infectious disease and central nervous system disorders.

Van Dyke discussed how an ongoing partnership helped Cloud develop its technology for creating drug candidates that can pervade the blood-brain barrier and the company's virtual model, in which it performs the

More from Strategy

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

More from Business